Indoor Air Pollution and Children With Asthma: An Intervention Trial (CAPS)

November 19, 2020 updated by: Yale University

Indoor Nitrogen Dioxide Exposure and Children With Asthma: An Intervention Trial

The purpose of this study is to determine whether reducing indoor exposure to NO2 and particles improves respiratory health in children with asthma.

Study Overview

Status

Completed

Conditions

Detailed Description

We have designed a randomized, double-blind, triple cross-over intervention study to examine the efficacy of indoor NO2 reduction on reducing asthma severity. Since particles and NO2 are both byproducts of combustion and associated with gas stove use, the intervention protocol includes a condition using a filter designed to remove particles also implicated in asthma exacerbations (e.g., coarse, fine and ultrafine particles including airborne mold spores and allergens) while leaving NO2 virtually untouched. Primary and secondary aims of the trial include, respectively, determining whether reducing exposure to NO2 and particles compared to a "control" (non-filtered) condition results in a clinically significant reduction in asthma severity measured by a difference in days of symptoms between intervention arms.

Families with asthmatic children age 5-11 will be recruited from selected communities using a: (1) flyers distributed in elementary schools, (2) postcards send to families from purchased mailing lists, (3) posters placed in community buildings (libraries, clinics, etc.), (4) online (Facebook, Craigslist), and (5) letter mailed to families targeted through Yale Joint Data Analytics Team (JDAT). Volunteers will be screened for preliminary eligibility based on household characteristics and active asthmatic status. Potentially eligible families will have homes with a gas cooking stove and seven rooms or fewer. Potentially eligible children will be aged 5-11; have asthma symptoms and/or medication use consistent with severity score categories 2 (mild persistent), 3 (moderate), or 4 (severe) during the previous 12 months; and reside at least 5 days and nights every week in the eligible home.

Households meeting these preliminary criteria will be asked to participate in passive NO2 sampling. A single Palmes tube will be sent to the home for placement in the main living space for one week. Families will be called after one week and instructed to cap and return the NO2 monitor in a pre-paid mailer. Families of children living in homes where the one-week integrated average NO2 concentration is ≥ 15 ppb will be invited to participate. We will permit enrollment of more than one eligible child per family. Participating families will be randomized into one of 6 treatment sequences each requiring 3 periods of 4-weeks preceded by a 1-week washout period. Randomization will be blocked so that for every 18 subjects randomized there will be 3 in each sequence. Randomization will be conducted blindly by the data management department such that each scheduled initial interview/air cleaner installation is assigned a treatment sequence (referring to machines and filters already on site). Minimization techniques will be used to balance the randomized allocation as necessary. Total subject participation time up to 18 weeks.

Study Type

Interventional

Enrollment (Actual)

116

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Connecticut
      • New Haven, Connecticut, United States, 06520
        • Yale University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

5 years to 11 years (Child)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • 5-11 years of age, enrolled in grades K-5 and living in the recruitment area (CT, MA)
  • [The screening questionnaire will determine asthma symptoms in the past 12 months (wheeze, persistent cough, shortness of breath, chest tightness); and asthma medication use in the past 12 months (short-acting β2-agonists, long-acting β2-agonists, inhaled steroids, oral steroids, theophylline, cromones, and/or leukotriene inhibitors). Based on symptoms and medication, asthma severity will be categorized with a score adapted from the Global Initiative for Asthma guidelines (1=mild transient, 2=mild persistent, 3=moderate, 4=severe). Only children in categories 2 (mild persistent, 3 (moderate) or 4 (severe) will be eligible.]
  • For potential subjects satisfying these inclusion criteria, a passive NO2 monitor will be sent to the home for placement in the main living space for one week. Families will be called after one week and instructed to cap and return the NO2 monitor in a pre-paid mailer. Families of children living in homes where the one-week integrated average NO2 concentration is ≥ 15 ppb will be invited to participate. We will permit the enrollment of more than one eligible child per family.

Exclusion Criteria:

  • Using steroid medication for a condition other than asthma
  • Chronic respiratory condition other than asthma
  • Intention to move or relocate within 6 months

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: NO2 Scrubber, then HEPA filter, then Control
Participants will have 3 periods of 4 weeks with each filter with a 1 week washout between phases in the order of NO2 Scrubber, then HEPA filter, then Control.
an NO2 scrubber that removes NO2 and particles
a HEPA filter that removes 95% of suspended particles ≥ 0.003 μm in size (but does not remove NO2)
a "control" filter designed to be the same size and weight as the other two filters, but filters neither NO2 nor particles
Experimental: NO2 Scrubber, then Control, then HEPA filter
Participants will have 3 periods of 4 weeks with each filter with a 1 week washout between phases in the order of NO2 Scrubber, then Control, then HEPA filter
an NO2 scrubber that removes NO2 and particles
a HEPA filter that removes 95% of suspended particles ≥ 0.003 μm in size (but does not remove NO2)
a "control" filter designed to be the same size and weight as the other two filters, but filters neither NO2 nor particles
Experimental: HEPA filter, then NO2 scrubber, then Control
Participants will have 3 periods of 4 weeks with each filter with a 1 week washout between phases in the order of HEPA filter, then NO2 scrubber, then Control
an NO2 scrubber that removes NO2 and particles
a HEPA filter that removes 95% of suspended particles ≥ 0.003 μm in size (but does not remove NO2)
a "control" filter designed to be the same size and weight as the other two filters, but filters neither NO2 nor particles
Experimental: HEPA filter, then Control, then NO2 scrubber
Participants will have 3 periods of 4 weeks with each filter with a 1 week washout between phases in the order of HEPA filter, then Control, then NO2 scrubber
an NO2 scrubber that removes NO2 and particles
a HEPA filter that removes 95% of suspended particles ≥ 0.003 μm in size (but does not remove NO2)
a "control" filter designed to be the same size and weight as the other two filters, but filters neither NO2 nor particles
Experimental: Control, then HEPA filter, then NO2 scrubber
Participants will have 3 periods of 4 weeks with each filter with a 1 week washout between phases in the order of Control, then HEPA filter, then NO2 scrubber
an NO2 scrubber that removes NO2 and particles
a HEPA filter that removes 95% of suspended particles ≥ 0.003 μm in size (but does not remove NO2)
a "control" filter designed to be the same size and weight as the other two filters, but filters neither NO2 nor particles
Experimental: Control, then NO2 scrubber, then HEPA filter
Participants will have 3 periods of 4 weeks with each filter with a 1 week washout between phases in the order of Control, then NO2 scrubber, then HEPA filter
an NO2 scrubber that removes NO2 and particles
a HEPA filter that removes 95% of suspended particles ≥ 0.003 μm in size (but does not remove NO2)
a "control" filter designed to be the same size and weight as the other two filters, but filters neither NO2 nor particles

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Days with symptoms
Time Frame: Final 14 days of intervention
The maximum of the following variables reported over the 2-week recall period: (1) number of days with wheezing, chest tightness, or persistent cough; (2) number of nights of sleep disturbance; (3) number of days when activities were affected.
Final 14 days of intervention

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Days of wheeze
Time Frame: Post 4 week intervention
As measured by self report
Post 4 week intervention
Night symptoms
Time Frame: Post 4 week intervention
As measured by self report
Post 4 week intervention
Rescue medication use
Time Frame: Post 4 week intervention
As measured by self report
Post 4 week intervention
Symptom Score
Time Frame: Last 4 weeks of intervention
The score is adapted from the Global Initiative for Asthma Guidelines which incorporates type and frequency of symptoms and medications. The symptom score portion, is a 5-level score calculated based on symptoms during the last 4-weeks of the intervention.
Last 4 weeks of intervention
Amount of Restricted Activity
Time Frame: Post 4 week intervention
Activity Restrictions as measured by self report
Post 4 week intervention
Number of Missed days of school
Time Frame: Post 4 week intervention
As measured by self report
Post 4 week intervention
Number of Hospitalizations
Time Frame: Post 4 week intervention
As measured by self report
Post 4 week intervention
Number of Emergency Room Visits
Time Frame: Post 4 week intervention
As measured by self report
Post 4 week intervention
Number of Doctors Visits
Time Frame: Post 4 week intervention
As measured by self report
Post 4 week intervention

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Principal Investigator: Brian Leaderer, PhD, MPH, Yale University
  • Principal Investigator: Michael Bracken, PhD MPH FACE, Yale University
  • Principal Investigator: Theodore Holford, PhD, Yale University
  • Principal Investigator: Janneane Gent, PhD, Yale University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 1, 2016

Primary Completion (Actual)

August 31, 2019

Study Completion (Actual)

August 31, 2019

Study Registration Dates

First Submitted

October 2, 2014

First Submitted That Met QC Criteria

October 2, 2014

First Posted (Estimate)

October 8, 2014

Study Record Updates

Last Update Posted (Actual)

November 23, 2020

Last Update Submitted That Met QC Criteria

November 19, 2020

Last Verified

November 1, 2020

More Information

Terms related to this study

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Asthma

Clinical Trials on NO2 Scrubber

3
Subscribe